Pralatrexate for Refractory Mycosis Fungoides in Two Japanese Patients

Overview

Journal J Dermatol

Specialty Dermatology

Date 2021 Jan 17

PMID 33454985

Authors

Mika Teraishi

Tokuko Oguro

Ema Kusume

Haruka Kobashi

Hozumi Sano

Ai Fujioka

Mayuko Yamamoto

Hideki Nakajima

Shigetoshi Sano

Affiliations

Soon will be listed here.

Abstract

Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced-stage cutaneous T-cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily-pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.

References

Amengual J, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E . A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2017; 131(4):397-407. PMC: 5790128. DOI: 10.1182/blood-2017-09-806737. View

Kitazume K, Akagawa Y, Wada S, Suzuki T, Fujita A . Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin. Case Rep Oncol. 2019; 12(2):529-536. PMC: 6696769. DOI: 10.1159/000501070. View

OConnor O, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B . Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29(9):1182-9. PMC: 3083873. DOI: 10.1200/JCO.2010.29.9024. View

Foss F, Horwitz S, Coiffier B, Bartlett N, Popplewell L, Pro B . Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk. 2012; 12(4):238-43. DOI: 10.1016/j.clml.2012.01.010. View

Olsen E, Whittaker S, Kim Y, Duvic M, Prince H, Lessin S . Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of.... J Clin Oncol. 2011; 29(18):2598-607. PMC: 3422534. DOI: 10.1200/JCO.2010.32.0630. View

Foss F, Parker T, Girardi M, Li A . Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clin Lymphoma Myeloma Leuk. 2018; 18(11):e445-e447. DOI: 10.1016/j.clml.2018.06.020. View

Wang E, OConnor O, She Y, Zelenetz A, Sirotnak F, Moore M . Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003; 44(6):1027-35. DOI: 10.1080/1042819031000077124. View

Duvic M, Kim Y, Zinzani P, Horwitz S . Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Clin Cancer Res. 2017; 23(14):3552-3556. PMC: 5511551. DOI: 10.1158/1078-0432.CCR-16-2064. View

Photiou L, Van Der Weyden C, McCormack C, Prince H . Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Curr Oncol Rep. 2018; 20(4):32. DOI: 10.1007/s11912-018-0678-x. View

10.

Talpur R, Thompson A, Gangar P, Duvic M . Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2014; 14(4):297-304. DOI: 10.1016/j.clml.2014.01.010. View

11.

Agar N, Wedgeworth E, Crichton S, Mitchell T, Cox M, Ferreira S . Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010; 28(31):4730-9. DOI: 10.1200/JCO.2009.27.7665. View

12.

Wood G, Wu J . Methotrexate and Pralatrexate. Dermatol Clin. 2015; 33(4):747-55. PMC: 5549926. DOI: 10.1016/j.det.2015.05.009. View

13.

Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T . Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017; 108(10):2061-2068. PMC: 5623731. DOI: 10.1111/cas.13340. View

14.

Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, Shimauchi T . Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group. J Dermatol. 2012; 40(1):2-14. DOI: 10.1111/j.1346-8138.2012.01639.x. View

15.

Horwitz S, Kim Y, Foss F, Zain J, Myskowski P, Lechowicz M . Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012; 119(18):4115-22. DOI: 10.1182/blood-2011-11-390211. View